“I am eager to partner with ProPharma’s global team to ensure superior clinical data science solutions are delivered to our valued client partners, further enhancing our position as the global leader in the life sciences sector.”
RALEIGH, N.C. (PRWEB)
August 02, 2023
ProPharma Group (ProPharma), the leading global provider of regulatory, clinical, and compliance services for the life sciences industry, and a portfolio company of Odyssey Investment Partners, today announced the appointment of Helen Hall as Global Head of Clinical Data Sciences, where she will lead clinical data management, as well as biostatistics and programming.
A seasoned leader in clinical research with over two decades of progressive experience, Hall brings an extensive knowledge base, renowned expertise, and a commendable track record of producing organizational and operational outcomes for globally recognized life sciences organizations. Prior to joining ProPharma, the world’s largest RCO (Research Consulting Organization), Hall served in several senior leadership capacities at Syneos Health (Synteract), most recently as Senior Vice President, Clinical Data Sciences and Biometrics.
Throughout her distinguished career, Hall has demonstrated exemplary leadership to achieve corporate, operational, and financial goals while strictly adhering to regulatory, Good Clinical Practice (GCP), Standard Operating Procedures (SOPs), and protocol requirements. Her countless achievementsmanaging diverse teams of data sciences and biometrics professionals, domestically and internationally, has enabled the cultivation of a collaborative, productive, and efficient atmosphere that is conducive to long-term and future-focused organizational growth.
Michael Stomberg, ProPharma’s Chief Executive Officer, said: “We are excited to welcome Helen to the team. Her proven history of driving successful results, combined with her industry expertise and acumen make her an ideal match for this pivotal role. Helen’s demonstrated leadership in data sciences, organizational transformation, team development, process creation and harmonization, and strategic client management fortify ProPharma’s commitment to improve the health and safety of patients.”
Upon her appointment, Hall shared, “I am thrilled to join ProPharma and leverage my experience in clinical research, data sciences, and biometrics to propel the company’s strategic objectives. I am eager to partner with ProPharma’s global team to ensure superior clinical data science solutions are delivered to our valued client partners, further enhancing our position as the global leader in the life sciences sector.”
ProPharma’s steadfast commitment to innovation and the ongoing advancement of its revolutionary Research Consulting Organization (RCO) model is reaffirmed with the appointment of Hall as the Global Head of Clinical Data Sciences. This strategic move ensures robust leadership and positions the organization to surpass its operational and financial targets through the delivery of unparalleled clinical data sciences worldwide.
About ProPharma
For the past 20 years, ProPharma has improved the health and wellness of patients by providing advice and expertise that empowers biotech, med device, and pharmaceutical organizations of all sizes to confidently advance scientific breakthroughs and introduce new therapies. As the world’s largest RCO (Research Consulting Organization), ProPharma partners with its clients through an advise-build-operate model across the complete product lifecycle. With deep domain expertise in regulatory sciences, clinical research solutions, quality and compliance, pharmacovigilance, medical information, and R&D technology, ProPharma offers an end-to-end suite of fully customizable consulting solutions that de-risk and accelerate our partners’ most high-profile drug and device programs.
For more information about ProPharma, please visit: https://www.propharmagroup.com.
Share article on social media or email: